FDA Agrees to Phase 2 Trial of HLX-0201 in Treating Fragile X

FDA Agrees to Phase 2 Trial of HLX-0201 in Treating Fragile X

310663

FDA Agrees to Phase 2 Trial of HLX-0201 in Treating Fragile X

A Phase 2a clinical trial of HLX-0201 in treating behavioral symptoms in people with fragile X syndrome was given U.S. Food and Drug Administration (FDA) approval to open, the therapy’s developer, Healx, announced. Recruitment for the trial (NCT04823052) should begin in the coming months, the company stated in a press release. HLX-0201 (sulindac) was initially approved as a non-steroidal anti-inflammatory drug (NSAID). The therapy, identified using Healx’s artificial intelligence (AI)-driven approach to drug discovery, was then validated in…

You must be logged in to read/download the full post.